Dismissal of Prevagen case deals tough blow to FTC
When the Federal Trade Commission and New York’s attorney general joined forces to sue Quincy Bioscience for deceptive advertising in promoting Prevagen, a dietary supplement, the enforcers came out guns blazing....
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: